Nageswaran Sivalingam

8PUBLICATIONS
2CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 16, 2026
Secretion of IL-6 and TGF-β2 by Colon Cancer Cells May Promote Resistance to Chemotherapy.

Sruthi Sritharan, Nageswaran Sivalingam

|Jul 02, 2025
A recent decade update on combating doxorubicin-induced toxicities.

Sruthi Sritharan, Nageswaran Sivalingam

|Feb 03, 2024
Doxorubicin-induced chemoresistance in Duke's type B colon adenocarcinoma cell line is aggravated in the presence of TGF-β2 through non-apoptotic cell death.

Sruthi Sritharan, Nageswaran Sivalingam

|Jun 18, 2022
Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Sruthi Sritharan, Sampurna Guha, Snoopy Hazarika

|Oct 07, 2020
Curcumin induces chemosensitization to doxorubicin in Duke's type B coloadenocarcinoma cell line.

Jeyan Jayarajan, Sruthy Angandoor, Sri Harsha Vedulla

Pageof 2